Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience

被引：12
作者：
Cerchione, Claudio [1 ]
Catalano, Lucio [1 ]
Pareto, Anna Emanuele [1 ]
Picardi, Marco [1 ]
Pane, Fabrizio [1 ]
机构：
[1] Hematol AOU Federico II, Naples, Italy
来源：
SUPPORTIVE CARE IN CANCER | 2015年 / 23卷 / 02期
关键词：
Bortezomib; Febrile Neutropenia; Lenalidomide; National Comprehensive Cancer Network; National Comprehensive Cancer Network;
D O I：
10.1007/s00520-014-2490-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：301 / +
页数：2
相关论文
共 50 条
  • [21] Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data
    Stork, M.
    Sevcikova, S.
    Brozova, L.
    Spicka, I
    Maisnar, V
    Minarik, J.
    Jungova, A.
    Gregora, E.
    Velichova, R.
    Hajek, R.
    Jelinek, T.
    Pour, L.
    NEOPLASMA, 2020, 67 (01) : 178 - 184
  • [22] The Impact of Baseline Risk Factors on the Incidence of Febrile Neutropenia in Breast Cancer Patients Receiving Chemotherapy with Pegfilgrastim Prophylaxis: A Real-World Data Analysis
    Li, Edward
    Schroader, Bridgette Kanz
    Campbell, David
    Campbell, Kim
    Wang, Weijia
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2021, 8 (01): : 106 - 115
  • [23] Use of cefepime, meropenem, or piperacillin/tazobactam as initial treatment for febrile neutropenia in patients with hematological malignancy - a real-life experience
    Karim, Najmul
    Kabir, Alamgir
    Islam, Manirul
    Biswas, Akhil Ranjan
    Wasim, Mohammed
    Alam, Mahbubul
    Chowdhury, Nobendu
    Islam, Mohammed Nadimul
    Tabassum, Tamanna
    Hasan, Mohammad Jahid
    EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2022, 34 (01)
  • [24] Use of cefepime, meropenem, or piperacillin/tazobactam as initial treatment for febrile neutropenia in patients with hematological malignancy — a real-life experience
    Najmul Karim
    Alamgir Kabir
    Manirul Islam
    Akhil Ranjan Biswas
    Mohammed Wasim
    Mahbubul Alam
    Nobendu Chowdhury
    Mohammed Nadimul Islam
    Tamanna Tabassum
    Mohammad Jahid Hasan
    The Egyptian Journal of Internal Medicine, 2022, 34
  • [25] Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/ Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
    Rodriguez-Otero, Paula
    Sirvent, Maialen
    Pilar Gonzalez-Rodriguez, Ana
    Lavilla, Esperanza
    Garcia de Coca, Alfonso
    Maria Arguinano, Jose
    Marti, Josep M.
    Cabanas, Valentin
    Motllo, Cristina
    de Cabo, Erik
    Encinas, Cristina
    Murillo, Ilda
    Angel Hernandez-Rivas, Jose
    Perez-Persona, Ernesto
    Casado, Felipe
    Sampol, Antonia
    Garcia, Ricarda
    Jesus Blanchard, Maria
    Anguita, Magdalena
    Paz Lafuente, Ana
    Inigo, Belen
    Lopez, Aurelio
    Ribas, Paz
    Arnao, Mario
    Maldonado, Roberto
    Blade, Joan
    Victoria Mateos, Maria
    Jose Lahuerta, Juan
    San Miguel, Jesus F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (06) : 413 - 420
  • [26] Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents
    Gaultney, J. G.
    Franken, M. G.
    Tan, S. S.
    Redekop, W. K.
    Huijgens, P. C.
    Sonneveld, P.
    Uyl-de Groot, C. A.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (01) : 41 - 47
  • [27] Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers
    Varga, Gergely
    David Toth, Andras
    Reka Szita, Virag
    Csukly, Zoltan
    Hardi, Apor
    Gaal-Weisinger, Julia
    Nagy, Zsolt
    Altai, Elvira
    Rencsik, Annamaria
    Plander, Mark
    Szendrei, Tamas
    Korad, Krisztina
    Radvanyi, Gaspar
    Rottek, Janos
    Deak, Beata
    Szaleczky, Erika
    Schneider, Tamas
    Kohl, Zoltan
    Kosztolanyi, Szabolcs
    Alizadeh, Hussain
    Lengyel, Zsuzsanna
    Modok, Szabolcs
    Borbenyi, Zita
    Lovas, Szilvia
    Varoczy, Laszlo
    Illes, Arpad
    Rajnics, Peter
    Masszi, Tamas
    Mikala, Gabor
    PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
  • [28] Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network
    Conticello, Concetta
    Romano, Alessandra
    Del Fabro, Vittorio
    Martino, Enrica Antonia
    Calafiore, Valeria
    Sapienza, Giuseppe
    Leotta, Valerio
    Parisi, Marina Silvia
    Markovic, Uros
    Garibaldi, Bruno
    Leotta, Salvatore
    Cotzia, Emilia
    Innao, Vanessa
    Mannina, Donato
    Neri, Santo
    Musso, Maurizio
    Scalone, Renato
    Cangialosi, Clotilde
    Acquaviva, Francesco
    Cardinale, Giovanni
    Merenda, Anxur
    Maugeri, Cinzia
    Uccello, Giuseppina
    Poidomani, Massimo
    Longo, Giuseppe
    Carlisi, Melania
    Tibullo, Daniele
    Di Raimondo, Francesco
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [29] Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience
    Alegre, Adrian
    Oriol-Rocafiguera, Albert
    Garcia-Larana, Jose
    Mateos, Maria-Victoria
    Sureda, Anna
    Martinez-Chamorro, Carmen
    Teresa Cibeira, Maria
    Aguado, Beatriz
    Knight, Robert
    Rosettani, Barbara
    LEUKEMIA & LYMPHOMA, 2012, 53 (09) : 1714 - 1721
  • [30] Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience
    Byun, Ja Min
    Yoon, Sung-Soo
    Koh, Youngil
    Kim, Inho
    Jo, Jaemin
    Park, Hyunkyung
    Lee, Jeong-Ok
    Lee, Jiyun
    ANTICANCER RESEARCH, 2019, 39 (09) : 5165 - 5170
12345